[09-15-2015] The U.S. Food and Drug Administration (FDA) is making changes to the requirements for monitoring, prescribing, dispensing, and receiving the schizophrenia drug clozapine, to address continuing safety concerns and current knowledge about a serious blood condition called severe neutropen